New framework for more effective vaccine vectors

September 20, 2012
New framework for more effective vaccine vectors
Credit: Thinkstock

Despite the development of new technologies for successful vaccination against contagious diseases and cancer, there is a lack of standard operation procedures (SOPs) and cross-comparison. European scientists built the framework for the systematic production, validation and comparison of effective vaccine vectors.

Prophylactic and therapeutic vaccines against contagious diseases and cancer have been developed recently based on recombinant and virus-like particles. These vaccines exhibited effectiveness and specificity that makes them promising weapons against many diseases. Despite the potential of this technology, there is still a lack of a standardised strategy for their cost-effective production and evaluation.

In order to promote the establishment of a robust platform for the development and evaluation of recombinant vaccines, the European Union funded the project 'Ration design and standardized evaluation of novel genetic vaccines' (Compuvac). The primary objective was the development of novel vaccines based on gold standard antigens and standardised procedures for their evaluation of efficacy and safety.

The data produced by the partners were stored, processed and presented in an interactive bioinformatics platform which was established by Compuvac. Furthermore, the procedures developed within Compuvac were validated through the development of a vaccine against (HCV).

A variety of vaccine vectors were engineered and tested in different model systems. The results were systematically validated for their quality and stored in the for novel genetic vaccine development process (GEVADSS) database with a standardised report of each vaccine vector tested. Consequently, an automatic multi-parametric analysis and comparison of the performance of the different vectors was performed.

This analysis led to the successful design of a HCV . The data and the conclusion of these analyses are represented in the online publication of the interactive database that can now be used by the scientific community to comparatively assess future vaccines.

Compuvac scientists managed to achieve a satisfying level of standardisation with relatively low intra- and interlaboratory variations. The achieved standardisation was essential for the comparison of vaccine vectors across different laboratories. The validated SOPs are available to the scientific community through the Compuvac website.

The collective efforts of Compuvac partners led to the successful implementation and release of a user-friendly software platform for vaccine vector development and evaluation complete with a database, GEVADSS. The results of the evaluation of more than 100 vectors expressing the same antigens are a unique source of information for the scientific community.

The pioneering achievements of the Compuvac consortium successfully introduced systems immunology in the field of vaccination. The database GEVADSS is an excellent tool which is amenable to further development and application to different fields.

Explore further: New development could increase flu vaccine supply

Related Stories

New development could increase flu vaccine supply

June 2, 2011

(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or compound ...

Recommended for you

Natural compound reduces signs of aging in healthy mice

October 27, 2016

Much of human health hinges on how well the body manufactures and uses energy. For reasons that remain unclear, cells' ability to produce energy declines with age, prompting scientists to suspect that the steady loss of efficiency ...

A metabolic switch to turn off obesity

October 27, 2016

You've tried all the diets. No matter: you've still regained the weight you lost, even though you ate well and you exercised regularly! This may be due to a particular enzyme in the brain: the alpha/beta hydrolase domain-6 ...

Mitochondria control stem cell fate

October 27, 2016

What happens in intestinal epithelial cells during a chronic illness? Basic research conducted at the Chair of Nutrition and Immunology at the Technical University of Munich (TUM) addressed this question by generating a new ...

Scientists develop 'world-first' 3-D mammary gland model

October 27, 2016

A team of researchers from Cardiff University and Monash Biomedicine Discovery Institute has succeeded in creating a three-dimensional mammary gland model that will pave the way for a better understanding of the mechanisms ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.